Sirona Biochem Corp. Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen Sirona Biochem Corp. in den nächsten Jahren?
Pro
?
W******* i* V********
?
M****
?
L*********** I********** f** d** n******* J****
Kontra
?
A****************
?
M************
?
U****************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Sirona Biochem Corp. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Sirona Biochem Corp. | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -1,21 % | -5,71 % | 18,71 % | 11,49 % | -0,60 % | -13,61 % | -61,85 % |
| Northwest Biotherapeutics Inc. | 0,00 % | -13,55 % | -8,84 % | -31,63 % | -34,95 % | -70,48 % | -87,36 % |
| Achieve Life Sciences Inc. | 0,93 % | 0,93 % | -4,42 % | 145,45 % | 45,95 % | 6,93 % | -10,74 % |
Kommentare
News
Is Dentsply Sirona Stock a Buy After a Company Director Purchased 15,000 Shares?
Gregory T. Lucier, a member of the Board of Directors of Dentsply Sirona (NASDAQ:XRAY), reported the purchase of 15,000 shares of common stock at an average price of $12.45 per share on March 9
